Xenon Pharmaceuticals Revenue 2012-2022 | XENE

Xenon Pharmaceuticals revenue from 2012 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Xenon Pharmaceuticals Annual Revenue
(Millions of US $)
2021 $18
2020 $32
2019 $7
2018 $
2017 $0
2016 $2
2015 $16
2014 $28
2013 $27
2012 $14
2011 $7
Xenon Pharmaceuticals Quarterly Revenue
(Millions of US $)
2022-09-30 $0
2022-06-30 $1
2022-03-31 $9
2021-12-31 $4
2021-09-30 $8
2021-06-30 $2
2021-03-31 $4
2020-12-31 $5
2020-09-30 $7
2020-06-30 $13
2020-03-31 $7
2019-12-31 $3
2019-09-30 $4
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31 $0
2017-09-30 $0
2017-06-30 $0
2017-03-31 $0
2016-12-31 $0
2016-09-30 $0
2016-06-30 $0
2016-03-31 $1
2015-12-31 $3
2015-09-30 $4
2015-06-30 $4
2015-03-31 $4
2014-12-31 $5
2014-09-30 $13
2014-06-30 $5
2014-03-31 $5
2013-12-31
2013-09-30 $11
2012-12-31
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.451B $0.018B
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Biohaven (BHVN) United States $1.240B 0.00
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00